tiprankstipranks
Advertisement
Advertisement
CervoMed Raises $10 Million in Direct Offering
PremiumCompany AnnouncementsCervoMed Raises $10 Million in Direct Offering
1M ago
CervoMed announces $10M registered direct offering priced at-the-market
Premium
The Fly
CervoMed announces $10M registered direct offering priced at-the-market
2M ago
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
Premium
Company Announcements
CervoMed Gains New Patent for Neflamapimod Dementia Therapy
2M ago
CervoMed announces $10.5M private placement
PremiumThe FlyCervoMed announces $10.5M private placement
2M ago
CervoMed Shareholders Back Board, Pay and Incentive Plan
Premium
Company Announcements
CervoMed Shareholders Back Board, Pay and Incentive Plan
2M ago
CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
Premium
Ratings
CervoMed: FDA-Aligned Phase 3 Path and Multiple Catalysts Underscore Buy Rating, Price Target Held at $27
3M ago
Neflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
PremiumRatingsNeflamapimod’s MRI and Connectivity Data Support Disease‑Modifying Potential in Dementia With Lewy Bodies and Underscore Buy Rating on CervoMed
3M ago
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
Premium
Company Announcements
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results
3M ago
CervoMed presents neflamapimod MRI data
Premium
The Fly
CervoMed presents neflamapimod MRI data
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100